Esteva FJ - Search Results

1

Breast carcinoma treatment received by women with disabilities compared with women without disabilities.

Caban ME, Nosek MA, Graves D, Esteva FJ, McNeese M. Caban ME, et al. Among authors: esteva fj. Cancer. 2002 Mar 1;94(5):1391-6. doi: 10.1002/cncr.10369. Cancer. 2002. PMID: 11920493 Free article.

2

Locally advanced breast cancer.

Esteva FJ, Hortobagyi GN. Esteva FJ, et al. Hematol Oncol Clin North Am. 1999 Apr;13(2):457-72, vii. doi: 10.1016/s0889-8588(05)70065-4. Hematol Oncol Clin North Am. 1999. PMID: 10363140 Review.

3

Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer.

Pusztai L, Esteva FJ, Cristofanilli M, Hung MC, Hortobagyi GN. Pusztai L, et al. Among authors: esteva fj. Cancer Treat Rev. 1999 Oct;25(5):271-7. doi: 10.1053/ctrv.1999.0132. Cancer Treat Rev. 1999. PMID: 10544071 Review.

4

Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer.

Esteva FJ, Soh LT, Holmes FA, Plunkett W, Meyers CA, Forman AD, Hortobagyi GN. Esteva FJ, et al. Cancer Chemother Pharmacol. 2000;46(5):382-6. doi: 10.1007/s002800000173. Cancer Chemother Pharmacol. 2000. PMID: 11127942

5

Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy.

Buchholz TA, Tucker SL, Erwin J, Mathur D, Strom EA, McNeese MD, Hortobagyi GN, Cristofanilli M, Esteva FJ, Newman L, Singletary SE, Buzdar AU, Hunt KK. Buchholz TA, et al. Among authors: esteva fj. J Clin Oncol. 2001 Apr 15;19(8):2240-6. doi: 10.1200/JCO.2001.19.8.2240. J Clin Oncol. 2001. PMID: 11304777

6

Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer.

Rivera E, Valero V, Esteva FJ, Syrewicz L, Cristofanilli M, Rahman Z, Booser DJ, Hortobagyi GN. Rivera E, et al. Among authors: esteva fj. Cancer Chemother Pharmacol. 2002 Apr;49(4):299-302. doi: 10.1007/s00280-001-0405-3. Epub 2001 Dec 18. Cancer Chemother Pharmacol. 2002. PMID: 11914909

7

Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer.

Booser DJ, Esteva FJ, Rivera E, Valero V, Esparza-Guerra L, Priebe W, Hortobagyi GN. Booser DJ, et al. Among authors: esteva fj. Cancer Chemother Pharmacol. 2002 Jul;50(1):6-8. doi: 10.1007/s00280-002-0464-0. Epub 2002 May 21. Cancer Chemother Pharmacol. 2002. PMID: 12111105 Clinical Trial.

8

Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma.

Wang J, Buchholz TA, Middleton LP, Allred DC, Tucker SL, Kuerer HM, Esteva FJ, Hortobagyi GN, Sahin AA. Wang J, et al. Among authors: esteva fj. Cancer. 2002 Jun 15;94(12):3107-14. doi: 10.1002/cncr.10585. Cancer. 2002. PMID: 12115341 Free article.

9

Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy.

Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, Jhingran A, Tucker SL, Pusztai L, Cristofanilli M, Esteva FJ, Hortobagyi GN, Sahin AA. Buchholz TA, et al. Among authors: esteva fj. Cancer J. 2003 Jan-Feb;9(1):33-41. doi: 10.1097/00130404-200301000-00007. Cancer J. 2003. PMID: 12602766

10

Molecular profiles of invasive mucinous and ductal carcinomas of the breast: a molecular case study.

Pusztai L, Sotiriou C, Buchholz TA, Meric F, Symmans WF, Esteva FJ, Sahin A, Liu ET, Hortobagi GN. Pusztai L, et al. Among authors: esteva fj. Cancer Genet Cytogenet. 2003 Mar;141(2):148-53. doi: 10.1016/s0165-4608(02)00737-9. Cancer Genet Cytogenet. 2003. PMID: 12606133

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

231 results

Search Page

Filters